Page 4 - Torrent Pharma

Torrent Pharma's net profit rises 7% at Rs 378 crore in April-June quarter

Torrent Pharma on Monday reported a 7 per cent increase in its profit after tax to Rs 378 crore for the June quarter. The company had reported a profit after tax (PAT) of Rs 354 crore in the year-ago quarter. Revenue for the first quarter of the current fiscal rose to Rs 2,591 crore as against Rs 2,347 crore in the year-ago period, Torrent Pharma said in a statement. The drug firm said its domestic revenue grew 14.5 per cent year-on-year to Rs 1,426 crore during the quarter. The company said its revenue also went up in Brazil and Germany by 3 per cent and 21 per cent, respectively. Revenue in the US market, however, declined by 2 per cent to Rs 293 crore, it added. Torrent Pharma shares ended 0.49 per cent down at Rs 2,051.50 apiece on the BSE.

Torrent Pharma surges 8%, hits record high post March quarter results

Torrent's branded generics business India continues to perform well with focus on curatio acquisition and focus on power brands besides consumer business foray.

Stocks to watch: Adani Ports, NMDC, HDFC Life, Apollo Hospitals, PTC Inds

Stocks to watch on May 31, 2023: From Adani Ports to Sun Pharma, here are top stocks to watch in Wednesday's trading session

Torrent Power posts Rs 484 cr Q4 net profit in, income grows to 6,133.70 cr

Torrent Power on Monday reported Rs 483.93 crore consolidated net profit in the March 2023 quarter, mainly on the back of higher revenues. The company had reported a consolidated net loss of Rs 487.37 crore in the quarter ended March 2022, a BSE filing showed. Its total income rose to 6,133.70 crore in the quarter from Rs 3,840.59 crore in the year-ago period. The consolidated net profit in the fiscal 2022-23 rose to Rs 2,164.67 crore from Rs 458.70 crore in the previous fiscal. Its total income in the fiscal increased to Rs 26,075.97 crore against Rs 14,492.65 crore in 2021-22. The board has recommended a final dividend of Rs 4 per equity share for 2022-23. This final dividend along with an interim dividend of Rs 22.00 per equity share works out to a total dividend of Rs 26.00 per equity share (including Rs 13.00 per equity share as a special dividend) for the 2022-23. The final dividend, if declared by the members at the ensuing AGM will be paid to the members, subject to deduc

Results preview: India business to put a spring in pharma's step

Hospitals to recover from sluggish Q3; diagnostics' growth rate at pre-Covid levels

Torrent Pharmaceuticals forays into OTC segment with calcium supplement

Torrent Pharmaceuticals on Tuesday said it has forayed into the over-the-counter segment in the country with Shelcal 500, a calcium supplement brand. With its composition of 500mg Calcium and 250 IU of Vitamin D3, Shelcal 500 helps optimise calcium absorption, increases bone density, improves muscle strength and helps boost immunity. The calcium is sourced from natural ingredients like oyster shell, having good absorption/bioavailability in the body. "With Shelcal's entry into OTC, the brand is poised to become the largest calcium supplement brand in India," Torrent Pharmaceuticals Director Aman Mehta said in a statement. According to studies, 40.6 per cent of Indians are calcium-deficient, while 79 per cent are Vitamin D-deficient.

NCLT stays Reliance Cap resolution process on Torrent Group's plea

The insolvency process of debt-ridden Reliance Capital Ltd (RCL) on Tuesday hit a roadblock as the NCLT Mumbai has stayed the resolution process on the plea of Torrent Group. The stay order was issued by the National Company Law Tribunal (NCLT) as the Ahmedabad-based Torrent Group challenged the revised bid from Hinduja Group, sources said. Torrent Group, which emerged as the highest bidder with an Rs 8,640 crore offer, had moved the NCLT-Mumbai against Hinduja Group's late revised bid, which it had submitted after the completion of the e-auction process on December 21. A day after the e-auction, Hinduja Group, the promoter of IndusInd Bank, revised its offer from Rs 8,110 crore to Rs 9,000 crore. This is the first time that an e-auction of this scale is taking place for the resolution of an NBFC (non-banking financial company) under the Insolvency and Bankruptcy Code (IBC). The decision of e-auction was taken at the behest of LIC and EPFO, which together control 35 per cent of th

Hinduja sweetens offer for RCap to counter Torrent group's winning bid

CoC decide whether Hinduja offer is legally valid or not as e-auction has ended

Stocks to Watch: Sula Vineyards, RIL, Spandana, Speciality Restaurants

Stocks to Watch Today: Shares of Sula Vineyards likely to list on a tepid note on Thursday.

Torrent Pharma, Boehringer Ingelheim India to co-market diabetes drug

Torrent Pharmaceuticals on Wednesday said it has inked a pact with Boehringer Ingelheim India to co-market diabetes drug and its combinations in the country. The company has inked an agreement to jointly sell Cospiaq (Empagliflozin), Cospiaq Met (Empagliflozin+ Metformin) and Xilingio (Empagliflozin+ Linagliptin). Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus. It is also indicated to reduce the risk of cardiovascular death, in adults with type 2 diabetes mellitus and established cardiovascular disease. "I am confident that the launch of Cospiaq, Cospiaq Met and Xilingio will further strengthen our overall diabetes and cardiovascular portfolios and bolster our position as a leading player in these high growth segments within the Indian pharmaceutical market," Torrent Pharmaceuticals Director Aman Mehta said in a statement. Boehringer Ingelheim India Managing Direct

After the anti-diabetic market, India's cardiac market in for a shake-up

After the anti-diabetic market, India's cardiac market in for a shake-up

Number of deals down 42% in October but matches pre-pandemic level: Report

According to GT Bharat's monthly Dealtracker, the biggest deal in October was Torrent Pharma's $250 million acquisition of Curatio Healthcare

Pharma shares may turnaound soon; Cipla, Sun Pharma, Granules can gain 20%

What do expect from pharma stocks over the next few weeks? Here's what technical charts suggest.

Torrent Pharmaceuticals net profit falls 1% on US, German markets

Brazil revenues for the quarter came in at Rs 185 crore, up by 19 percent. US revenues for the quarter were Rs 292 crore, up by 3 percent. Germany revenue was down 12 percent to Rs 220 crore

Torrent Pharma Q2 net profit declines marginally to Rs 312 crore

Torrent Pharmaceuticals on Friday reported a marginal decline in its consolidated net profit at Rs 312 crore for the second quarter ended September 2022. The company had posted a consolidated net profit of Rs 316 crore in the year-ago period. Revenue from operations rose to Rs 2,291 crore in the July-September quarter as against Rs 2,137 crore in the year-ago period, Torrent Pharma said in a statement. The company said its domestic revenue stood at Rs 1,224 crore during the period under review. The drug firm also reported robust sales across various international markets like the US, and Brazil, it added. Shares of the company on Friday ended 0.99 per cent down at Rs 1,578 apiece on the BSE.

Stocks to Watch: Nykaa, Ramco Cements, Blue Dart, Zomato, Torrent Pharma

Stock to watch today: Nykaa's board meeting will be held on October, 3 to consider and approve the issuance of bonus shares

Torrent Pharma to acquire Curatio Healthcare for Rs 2,000 cr; stock down 6%

ICICI Securities is positive on Torrent's ability of faster integration and turnaround of acquired assets in the domestic space

Torrent Pharma acquires cosmetic derma player Curatio for Rs 2,000 cr

First major acquisition by Aman Mehta after taking charge at Torrent Pharma in August

Indian generic formulation-makers level of capex declining: Candle Partners

Candle Partners study shows that from the peak of 30% of gross block in FY16, the capex is down to 9-10% of gross block

Torrent group to make Rs 2,900-cr bid for Reliance Nippon Life Insurance

Reliance Capital is undergoing a bankruptcy process and the administrator had sought offers for the entire company and for its various business clusters